Oncolytics reports enhanced immune activity with pelareorep in multiple myeloma trial
ONCY•Oncolytics Biotech reported immune activation and tumor-cell changes linked to increased cell death in heavily pretreated patients with relapsed or refractory multiple myeloma. The findings will be presented at the American Society of Hematology annual meeting on December 12, 2026.
1. Trial findings
Oncolytics Biotech announced Phase 1b/2 trial data showing pelareorep-associated immune activation in heavily pretreated patients with relapsed or refractory multiple myeloma. Responders showed stronger expansion of immune cells and fewer signs of immune-cell exhaustion than nonresponders; the findings will be presented on December 12, 2026.
